Design of the value of imaging in enhancing the wellness of your heart (VIEW) trial and the impact of uncertainty on power

Clinical Trials

Volumn 9, Issue 2, 2012, Pages 232-246

  Ambrosius, Walter T ^a   Polonsky, Tamar S ^b   Greenland, Philip ^c   Goff, David C ^a   Perdue, Letitia H ^a   Fortmann, Stephen P ^d   Margolis, Karen L ^e   Pajewski, Nicholas M ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL EFFECTIVENESS; CORONARY ARTERY CALCIUM TEST; COST EFFECTIVENESS ANALYSIS; FOLLOW UP; HEART ARREST; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; RISK FACTOR; SCREENING TEST; STROKE;

AGED; CALCIUM; CORONARY ARTERY DISEASE; DIAGNOSTIC IMAGING; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SAMPLE SIZE; TOMOGRAPHY, X-RAY COMPUTED; UNCERTAINTY;

EID: 84861795137     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774512436882     Document Type: Article

References (41)

1. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998 ; 97: 1837-47
2. Greenland P, LaBree L, Azen SP, Doherty TM, Detrano RC. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004 ; 291: 210-15
3. Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med. 2008 ; 358: 1336-45
4. Lakoski SG, Greenland P, Wong ND, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as 'low risk' based on Framingham risk score: The Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med. 2007 ; 167: 2437-42
5. Polonsky TS, McClelland RL, Jorgensen NW, et al. Coronary artery calcium score and risk classification for coronary heart disease prediction. JAMA. 2010 ; 16: 1610-16
6. Mohlenkamp S, Lehmann N, Greenland P, et al. on behalf of the Heinz Nixdorf Recall Study Investigators. Coronary artery calcium score improves cardiovascular risk prediction in persons without indication for statin therapy. Atherosclerosis. 2011 ; 215: 229-36
7. Hackam DG, Shojania KG, Spence JD, et al. Influence of Noninvasive Cardiovascular Imaging in Primary Prevention: Systematic Review and Meta-analysis of Randomized Trials. Arch Intern Med. 2011 ; 171: 977-82
8. Lauer MS. Elements of danger-The case of medical imaging. N Engl J Med. 2009 ; 361: 841-43
9. Greenland P, Polonsky TS. Time for a policy change for coronary artery calcium testing in asymptomatic people?. J Am Coll Cardiol. 2011 ; 58 (16). 1702-04
10. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS): National Health and Nutrition Examination Survey Questionnaire, Examination Protocol, and Laboratory Protocol. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Hyattsville, MD, 2005-2008. Available at http://www.cdc.gov/nchs/nhanes.htm (accessed 7 August 2011).
11. WebMD. The 10 most prescribed drugs. Available at http://www.webmd.com/ news/20110420/the-10-most-prescribed-drugs (accessed 22 November 2011).
12. Consumer Reports. The statin drugs. Available at http://www. consumerreports.org/health/resources/pdf/best-buy-drugs/Statins-RxTrend-FINAL- Feb2007.pdf (accessed 22 November 2011).
13. Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. N Engl J Med. 2011 ; 365: 285-87
14. United States Food and Drug Administration. Available at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm257884.htm (accessed 15 August 2011).
15. Bild DE, Bluemke DA, Burke GL, et al. Multi-ethnic study of atherosclerosis: Objectives and design. Am J Epidemiol. 2002 ; 156: 871-81
16. Spiegelhalter DJ, Abrams KR, Myles JP Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Chichester: Wiley ; 2004: 193-94.
17. O'Hagan A, Stevens JW, Campbell MJ. Assurance in clinical trial design. Pharm Stat. 2005 ; 4: 187-201
18. Fay MP, Halloran ME, Follmann DA. Accounting for variability in sample size estimation with applications to nonadherence and estimation of variance and effect size. Biometrics. 2007 ; 63: 465-74
19. Julious SA, Owen RJ. Sample size calculations for clinical studies allowing for uncertainty about the variance. Pharm Stat. 2006 ; 5: 29-37
20. Ambrosius WT, Lange EM, Langefeld CD. Power for genetic association studies with random allele frequencies and genotype distributions. Am J Human Genet. 2004 ; 74: 683-93
21. Ambrosius WT, Mahnken JD. Power for studies with random group sizes. Stat Med. 2010 ; 29: 1137-44
22. Okwuosa TM, Greenland P, Ning H, et al. Distribution of coronary artery calcium scores by Framingham 10-year risk strata in the MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol. 2011 ; 57 (18). 1838-45
23. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA. 2009 ; 302: 2104-10
24. Rozanski A, Gransar H, Shaw LJ, et al. Impact of Coronary Artery Calcium Scanning on Coronary Risk Factors and Downstream Testing: The EISNER (Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research) prospective randomized trial. J Am Coll Cardiol. 2011 ; 57: 1622-32
25. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomized Trials. Lancet. 2010 ; 376: 1670-81
26. Server PS, Dahlaof B, Poulter NR, et al. for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet. 2003 ; 361: 1149-58
27. LaRosa JC, Grundy SM, Waters DD, et al. for the Treating to New Targets (TNT) Investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 ; 352: 1425-35
28. Julious SA Sample Sizes for Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC ; 2010 :
29. Delahoy PJ, Magliano DJ, Webb K, Grobler M, Liew D. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clin Ther. 2009 ; 31: 236-44
30. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285: 2486-97
31. Food and Drug Administration. Available at http://www.fda.gov/Drugs/ DrugSafety/ucm256581.htm (accessed 7 August 2011).
32. Spiegelhalter DJ, Freedman LS, Blackburn PR. Monitoring clinical trials: Conditional or predictive power?. Control Clin Trials. 1986 ; 7: 8-17
33. Hammersley JM, Handscomb DC Monte Carlo Methods. London: Methuen & Co. Ltd. ; 1964 :
34. Garthwaite PH, Kadane JB, O'Hagan A. Statistical methods for eliciting probability distributions. J Am Stat Assoc. 2005 ; 100 (470). 680-700
35. Oakley JE, O'Hagan A. Uncertainty in prior elicitations: A nonparametric approach. Biometrika. 2007 ; 94 (2). 427-41
36. SHeffield ELicitation Framework (SHELF). Available at http://www.tonyohagan.co.uk/shelf/ (accessed 8 August 2011).
37. Proschan MA, Lan KKG, Wittes JT Statistical Monitoring of Clinical Trials: A Unified Approach. New York: Springer ; 2006 :
38. Elashoff JD nQuery Advisor Version 7.0 User's Guide. CA: Los Angeles ; 2007 :
39. SAS/STAT 9.2 User's Guide. Cary, NC: SAS Institute ; 2008: 4809-5039.
40. Kotz S, Balakrishnan N, Johnson NL Continuous Multivariate Distributions, Volume 1: Models and Applications. 1: Models and Applications (2nd edn). Wiley, New York, 2000. New York: Wiley ; 2000 :
41. Gelman A, Carlin JB, Stern HS, Rubin DB Bayesian Data Analysis. Boca Raton, FL: Chapman & Hall/CRC ; 1995 :